The world’s hottest big drug company had good news for more than just its own shareholders. Investors in companies focused on hepatitis C treatments also had new reasons to celebrate.
AbbVie shares rose 14% to record highs after reporting strong fourth-quarter results on Friday, and they have doubled over the past year. There was much for investors to admire. Fourth-quarter revenue from Humira, the world’s best-selling drug, grew by 14% from a year ago to $4.9 billion, boosted by higher volume and price increases. And AbbVie... To Read the Full Story Subscribe Sign In